Alvin Ha

Alvin Ha

Auto-generated profile, based on publicly available information

Alvin Ha

Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA 94143; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA USA 94158

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2022 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
BSBrian R. Shy
Brian R. Shy
VVVivasvan S. Vykunta
Vivasvan S. Vykunta
AHAlvin Ha
Alvin Ha
ATAlexis Talbot
Alexis Talbot
TRTheodore L. Roth
Theodore L. Roth
AMAlex Marson
Alex Marson

21 October 2025 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
LGLaine Goudy
Laine Goudy
AHAlvin Ha
Alvin Ha
ABAshir A. Borah
Ashir A. Borah
JUJennifer M. Umhoefer
Jennifer M. Umhoefer
LCLauren Chow
Lauren Chow
LGLuke A. Gilbert
Luke A. Gilbert
Targeted epigenetic engineering of gene expression in cell therapies would allow programming of desirable phenotypes without many of the challenges and safety risks associated with double-strand break-based genetic editing approaches. Here, we develop an all-RNA platform for efficient, durable and multiplexed epigenetic programming in primary human T cells, stably turning endogenous genes off or on using CRISPRoff and CRISPRon epigenetic editors. We achieve epigenetic programming of diverse targeted genomic elements without the need for sustained expression of CRISPR systems. CRISPRoff-mediated gene silencing is maintained through numerous cell divisions, T cell stimulations and in vivo adoptive transfer, avoiding cytotoxicity or chromosomal abnormalities inherent to multiplexed Cas9-mediated genome editing. Lastly, we successfully combined genetic and epigenetic engineering using orthogonal CRISPR Cas12a–dCas9 systems for targeted chimeric antigen receptor (CAR) knock-in and CRISPRoff silencing of therapeutically relevant genes to improve preclinical CAR-T cell-mediated in vivo tumor control and survival.

17 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
GRGokul N. Ramadoss
Gokul N. Ramadoss
SNSamali J. Namaganda
Samali J. Namaganda
MKManasi M. Kumar
Manasi M. Kumar
JHJennifer R. Hamilton
Jennifer R. Hamilton
RSRohit Sharma
Rohit Sharma
BCBruce R. Conklin
Bruce R. Conklin
Genome editing is poised to revolutionize treatment of genetic diseases, but poor understanding and control of DNA repair outcomes hinders its therapeutic potential. DNA repair is especially understudied in nondividing cells like neurons, limiting the efficiency and precision of genome editing in many clinically relevant tissues. Here, we address this barrier by using induced pluripotent stem cells (iPSCs) and iPSC-derived neurons to examine how postmitotic human neurons repair Cas9-induced DNA damage. CRISPR editing outcomes differ dramatically in neurons compared to genetically identical dividing cells: neurons take longer to fully resolve this damage, and upregulate non-canonical DNA repair factors in the process. Manipulating this response with chemical or genetic perturbations allows us to direct DNA repair toward desired editing outcomes in nondividing human neurons, cardiomyocytes, and primary T cells. By studying DNA repair in clinically relevant cells, we reveal unforeseen challenges and opportunities for precise therapeutic editing.

10 December 2025 in Molecular Therapy
Verified
Journal Article
Open access
AHAlvin S. Ha
Alvin S. Ha
NKNechama Kalter
Nechama Kalter
MRMichael Rosenberg
Michael Rosenberg
LALuis A. Acevedo
Luis A. Acevedo
BLBrianna Liang
Brianna Liang
JEJonathan H. Esensten
Jonathan H. Esensten
Biallelic germline deficiency of IL2RA causes a rare autoimmune disease with impaired regulatory T cell (Treg) function and IL-2 signaling. Definitive treatment is currently limited to allogeneic hematopoietic stem cell transplantation, which carries significant morbidity and mortality risks. We previously identified a family with three siblings affected by compound heterozygous mutations in IL2RA, resulting in dysfunctional Tregs. Here, we introduce a novel therapeutic approach involving ex-vivo generation of gene-corrected autologous regulatory T cells (gcTregs). One of the two disease-causing mutations in patient-derived Tregs was corrected with CRISPR-Cas9-mediated homology-directed repair, restoring IL2RA expression. The resulting gcTregs demonstrated robust suppressive activity in vitro. Clinical-scale manufacturing from a patient with IL2RA deficiency showed efficient gene correction, restored IL2RA expression, and functional equivalence to healthy donor Tregs. This work establishes a Good Manufacturing Practice (GMP)-compatible manufacturing process for personalized gcTreg therapies, potentially providing a safer treatment option for patients with IL2RA deficiency as well as a framework for treating other inborn errors of immunity.

27 February 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
KSKonlin Shen
Konlin Shen
JFJake J. Flood
Jake J. Flood
ZZZhihuizi Zhang
Zhihuizi Zhang
AHAlvin Ha
Alvin Ha
BSBrian R. Shy
Brian R. Shy
SDShawn Douglas
Shawn Douglas
Long single-stranded DNA (ssDNA) is a versatile molecular reagent with applications including RNA- guided genome engineering and DNA nanotechnology, yet its production is typically resource-intensive. We introduce a novel method utilizing an engineered E. coli “helper” strain and phagemid system that simplifies long ssDNA generation to a straightforward transformation and purification procedure. Our method obviates the need for helper plasmids and their associated contamination by integrating M13mp18 genes directly into the E. coli chromosome. We achieved ssDNA lengths ranging from 504 to 20,724 nucleotides with titers up to 250 μg/L following alkaline-lysis purification. The efficacy of our system was confirmed through its application in primary T cell genome modifications and DNA origami folding. The reliability, scalability, and ease of our approach promises to unlock new experimental applications requiring large quantities of long ssDNA.